VISION & MISSION

IPMG seeks to be the trusted partner to the government of Indonesia and other stakeholders and to play an important role in improving the healthcare system through the core strengths of its members; i.e., medical innovation and manufacturing of products that meet international standards of pharmaceutical quality and safety.

COMMITMENT

As an organization, IPMG is committed to working with all healthcare sector stakeholders and to fully support government programs and regulations. IPMG and its members assiduously strive to ensure Indonesians have access to quality healthcare products.

ROLE

IPMG communicates the commitment and contribution of R&D-based pharmaceutical manufacturers in broadening access to innovative medicines, vaccines and biologics as well as in advocating and providing recommendations for the advancement of an effective and integrated healthcare system in Indonesia

IPMG News

Diabetes patients in Jakarta increased to 3.4% in 2018 compared to 2.5% in 2013. The number made Jakarta as the capital city with the highest number of diabetes prevalence in Indonesia. To overcome the issue, the Jakarta administration has formed a collaboration with global health company Novo Nordisk and Denmark Embassy to run the Cities Changing Diabetes (CCD) program. This program is aimed at mapping an issue, sharing solutions, and encouraging real actions to fight against diabetes and obesity in Jakarta.

Industry

The Health Ministry has formed a special team to prevent and handle frauds, which cause a financial crisis in the BPJS Kesehatan. The establishment of the special team is stipulated under Health Ministerial Regulation No. 16/2019 on Prevention and Handle of Frauds in Implementation of Health Insurance Program in National Social Security System. Based on the regulation, the team is set in the central to provincial administrations. For central administration level, the team consists of the Health Ministry, the Corruption Eradication Commission, as well as related ministries and agencies.

Kimia Farma has developed a number of active pharmaceutical ingredients (API) plants, which will create independence and reduce dependency on API import in a long term. Danareksa Sekuritas analyst Natalia Sutanto said Kimia Farma expected to immediately complete the construction of API plants, planning to commence commercial production in early 2020. The development of API plant was done through Kimia Farma Shungwun Pharmacopia (KFSP), a joint venture company of Kimia Farma and Shungwun Pharmacopia Indonesia. Natalia added that the plants can also support the government’s program in cutting API import for pharmaceutical industry.

Kimia Farma and Telekomunikasi Indonesia (Telkom) implemented Internet of Things (IoT) to support machines that produce drugs. The IoT implementation is claimed to have increased efficiency and productivity of this drugs manufacturer. Kimia Farma ITPT General Manager Ervan Belyadi Suryadi said that Kimia Farma is operating two of 11 plants in Cikarang, Bekasi regency, and Banjaran, Bandung regency. The IoT implementation has been proven effective in boosting performance of plant in Cikarang which focuses on producing raw materials and plant in Banjaran which produces drugs.

Regulation

The Indonesian Ulema Council’s Assessment Institute for Foods, Drugs and Cosmetics (LPPOM MUI) in 31 provinces filed a judicial review against Halal Product Guarantee Law to the Constitutional Court. However, the central LPPOM MUI will take over the judicial review by prioritizing a dialogue, but remains accommodating aspirations from LPPOM MUI in the regions. LPPOM MUI Director Lukmanul Hakim said that there's possibly an information on halal certification that raises concerns of the LPPOM MUI in the regions.